Novo Nordisk Inc. v. Brooksville Pharmaceuticals Inc.

  1. November 09, 2023

    Novo's Suit Over Compounded Weight-Loss Drug Is Tossed

    A Florida federal judge has issued an order dismissing Novo Nordisk Inc.'s suit against a Florida independent pharmacy for selling compounded semaglutide, a peptide also found in Ozempic, Novo's blockbuster diabetes drug used off-label for weight loss, ruling that the pharmaceutical company's claim is preempted by the federal Food, Drug and Cosmetic Act.

  2. August 16, 2023

    Fla. Pharmacy Says Obesity Drug Suit Is Preempted By FDCA

    A Florida pharmacy accused by Novo Nordisk of selling a compounded version of a popular weight loss drug said the pharmaceutical company lacks standing to sue in federal court because it can't preempt the U.S. Food and Drug Administration, which has sole authority to investigate whether drugs are safe.

  3. July 07, 2023

    Novo Nordisk Hits Pharmacies With Suits Over Ozempic

    Novo Nordisk has filed a series of lawsuits asking a pair of federal courts to stop various compounding pharmacies from doling out drugs with allegedly the same active ingredient as certain Novo Nordisk brand-name drugs meant to fight diabetes and help with weight loss.